Skip to Content
Merck

tRNA synthetase counteracts c-Myc to develop functional vasculature.

eLife (2014-06-19)
Yi Shi, Xiaoling Xu, Qian Zhang, Guangsen Fu, Zhongying Mo, George S Wang, Shuji Kishi, Xiang-Lei Yang
ABSTRACT

Recent studies suggested an essential role for seryl-tRNA synthetase (SerRS) in vascular development. This role is specific to SerRS among all tRNA synthetases and is independent of its well-known aminoacylation function in protein synthesis. A unique nucleus-directing domain, added at the invertebrate-to-vertebrate transition, confers this novel non-translational activity of SerRS. Previous studies showed that SerRS, in some unknown way, controls VEGFA expression to prevent vascular over-expansion. Using in vitro, cell and animal experiments, we show here that SerRS intervenes by antagonizing c-Myc, the major transcription factor promoting VEGFA expression, through a tandem mechanism. First, by direct head-to-head competition, nuclear-localized SerRS blocks c-Myc from binding to the VEGFA promoter. Second, DNA-bound SerRS recruits the SIRT2 histone deacetylase to erase prior c-Myc-promoted histone acetylation. Thus, vertebrate SerRS and c-Myc is a pair of 'Yin-Yang' transcriptional regulator for proper development of a functional vasculature. Our results also discover an anti-angiogenic activity for SIRT2.DOI: http://dx.doi.org/10.7554/eLife.02349.001.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sirtuin 2 human, recombinant, expressed in E. coli, ≥80% (SDS-PAGE)